ConductScience.org, home

Paper28325865

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Fischer K and 26 others. Blood, 2017. Cited by 101 papers, by iCite.

Cite this record

ConductScience Library. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Papers, record 28325865. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28325865

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
PubMed
Journal
Blood
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Letter, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
101
iCite
Relative citation ratio, by iCite
2.97
iCite
Revised in PubMed
2021-02-02
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fischer KKirsten
2Al-Sawaf OOthman
3Fink AMAnna-Maria
4Dixon MMark
5Bahlo JJasmin
6Warburton SSimon
7Kipps TJThomas J
8Weinkove RRobert
9Robinson SSue
10Seiler TTill
11Opat SStephen
12Owen CCarolyn
13López JJavier
14Humphrey KKathryn
15Humerickhouse RRod
16Tausch EEugen
17Frenzel LLukas
18Eichhorst BBarbara
19Wendtner CMClemens-M
20Stilgenbauer SStephan

Source PubMed

See all 27 authorsDownload CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Bridged Bicyclo Compounds, HeterocyclicMajor topic
Leukemia, Lymphocytic, Chronic, B-CellMajor topic
SulfonamidesMajor topic
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in28705863Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.https://conductscience.org/library/papers/28705863

Source PubMed

Download CSV of comments and corrections

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126639348Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.N Engl J Med2016https://conductscience.org/library/papers/26639348PubMed
227178240Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.Lancet Oncol2016https://conductscience.org/library/papers/27178240PubMed
323291630ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.Nat Med2013https://conductscience.org/library/papers/23291630PubMed
426472752Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.Blood2016https://conductscience.org/library/papers/26472752PubMed
524401022Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.N Engl J Med2014https://conductscience.org/library/papers/24401022PubMed
622331940
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
J Clin Oncol2012https://conductscience.org/library/papers/22331940PubMed
728089635Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.Lancet Oncol2017https://conductscience.org/library/papers/28089635PubMed
822591390Therapy of elderly/comorbid patients with chronic lymphocytic leukemia.Curr Pharm Des2012https://conductscience.org/library/papers/22591390PubMed
927573660
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
J Clin Oncol2016https://conductscience.org/library/papers/27573660PubMed

Download CSV of references

Cited by59

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.

PMIDTitleJournalYearIn PapersSource
41978941Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.Eur J Haematol2026https://conductscience.org/library/papers/41978941PubMed
41681925The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System.Cancers (Basel)2026https://conductscience.org/library/papers/41681925PubMed
41368078Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets.Hemasphere2025https://conductscience.org/library/papers/41368078PubMed
39871707Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.Am J Hematol2025https://conductscience.org/library/papers/39871707PubMed
39060763Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.Discov Oncol2024https://conductscience.org/library/papers/39060763PubMed
38835348Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them.Cancer Drug Resist2024https://conductscience.org/library/papers/38835348PubMed
37686667The Five "Ws" of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When.Cancers (Basel)2023https://conductscience.org/library/papers/37686667PubMed
36334238A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.Pharmacoecon Open2023https://conductscience.org/library/papers/36334238PubMed
35983732Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.Leuk Lymphoma2022https://conductscience.org/library/papers/35983732PubMed
35309786Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?Hemasphere2019https://conductscience.org/library/papers/35309786PubMed
35066728
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
Clin Exp Med2023https://conductscience.org/library/papers/35066728PubMed
34943974Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.Cells2021https://conductscience.org/library/papers/34943974PubMed
34938664Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.Front Oncol2021https://conductscience.org/library/papers/34938664PubMed
34733320Development of a 3 RNA Binding Protein Signature for Predicting Prognosis and Treatment Response for Glioblastoma Multiforme.Front Genet2021https://conductscience.org/library/papers/34733320PubMed
34168283Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.Leukemia2021https://conductscience.org/library/papers/34168283PubMed
33578607Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.Medicine (Baltimore)2021https://conductscience.org/library/papers/33578607PubMed
33519195Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.Patient Prefer Adherence2021https://conductscience.org/library/papers/33519195PubMed
33275668Chemotherapy-free frontline therapy for CLL: is it worth it?Hematology Am Soc Hematol Educ Program2020https://conductscience.org/library/papers/33275668PubMed
32934355Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.Leukemia2021https://conductscience.org/library/papers/32934355PubMed
32542586Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm.Curr Hematol Malig Rep2020https://conductscience.org/library/papers/32542586PubMed

See all 59 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28325865

GET https://conductscience.org/api/papers/v1/28325865/authors?page=2